Literature DB >> 1838493

The effects of neuropeptide Y on myocardial contractility and coronary blood flow.

S J Awad1, R Einstein, E K Potter, D P Richardson.   

Abstract

1. This study was designed to assess the effects of exogenous neuropeptide Y (NPY) on cardiac contractility and coronary blood flow (CBF) in anaesthetized dogs and to evaluate the effect of NPY on the responses to sympathetic and parasympathetic stimulation and to inotropic agents. 2. Bolus doses of NPY (500 micrograms), administered via the femoral vein, increased mean arterial pressure. The pressor effect was associated with reductions in heart rate, CBF and cardiac contractility. 3. The effects of NPY (500 micrograms) on contractility and CBF were compared with that of vasopressin (VP) (1 unit). For similar reductions in CBF, NPY and VP had similar negative inotropic effects. Thus, it is likely that the negative inotropic response to NPY is not due to a direct effect of NPY on the heart muscle but is largely due to coronary vasoconstriction. 4. In the presence of NPY (500 micrograms, i.v.), there was an inhibition of the positive inotropic response to stimulation of the left cardiac sympathetic nerve (2 or 5 Hz, 0.05 ms). NPY also inhibited the negative inotropic response and chronotropic response to vagal stimulation (2, 3 or 5 Hz, 0.05 ms). 5. Dose-response curves were obtained for the inotropic, chronotropic and pressor responses to cumulative infusions of noradrenaline (n = 6) and dobutamine (n = 6). NPY had no effect on these dose-response curves. 6. The effect of NPY on the responses to salbutamol and impromidine was assessed. NPY did not alter the positive inotropic, chronotropic or depressor responses to these agonists. 7. Our results indicate that NPY has direct, postsynaptic vasoconstrictor activity and the reduction in myocardial contractility and heart rate are due to a combination of coronary vasoconstriction, baroreceptor reflex activation and presynaptic inhibition of transmitter release from sympathetic nerves. The welldocumented inhibitory effect of NPY on the chronotropic response to parasympathetic stimulation was confirmed and similar inhibition of the inotropic response to both sympathetic and parasympathetic stimulation was demonstrated. Since there was no modulation of the inotropic effects of exogenous alpha- and beta-adrenoceptor or H2-receptor agonists, it is concluded that the effects of NPY on myocardial contractility are exerted presynaptically.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1838493      PMCID: PMC1908260          DOI: 10.1111/j.1476-5381.1991.tb12407.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  31 in total

1.  A device for measuring myocardial contractility.

Authors:  A H Goodman; J A Angus; R Einstein; L B Cobbin
Journal:  Med Biol Eng       Date:  1972-07

2.  Prolonged non-adrenergic inhibition of cardiac vagal action following sympathetic stimulation: neuromodulation by neuropeptide Y?

Authors:  E K Potter
Journal:  Neurosci Lett       Date:  1985-03-15       Impact factor: 3.046

3.  Neuropeptide Y (NPY) and the pig heart: release and coronary vasoconstrictor effects.

Authors:  A Rudehill; A Sollevi; A Franco-Cereceda; J M Lundberg
Journal:  Peptides       Date:  1986 Sep-Oct       Impact factor: 3.750

4.  Coronary constriction due to neuropeptide Y: alleviation with cyclooxygenase blockers.

Authors:  S E Martin; R E Patterson
Journal:  Am J Physiol       Date:  1989-09

5.  The negative inotropic effect of neuropeptide Y on the ventricular cardiomyocyte.

Authors:  H M Piper; B C Millar; B J McDermott
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-09       Impact factor: 3.000

6.  Neuropeptide-Y. A peptide found in human coronary arteries constricts primarily small coronary arteries to produce myocardial ischemia in dogs.

Authors:  M F Maturi; R Greene; E Speir; C Burrus; L M Dorsey; D R Markle; M Maxwell; W Schmidt; S R Goldstein; R E Patterson
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

7.  Neuropeptide Y-induced pressor responses: activation of a non-adrenergic mechanism, potentiation by reserpine and blockade by nifedipine.

Authors:  Y Mabe; K Tatemoto; J P Huidobro-Toro
Journal:  Eur J Pharmacol       Date:  1985-10-08       Impact factor: 4.432

8.  Coronary artery infusion of neuropeptide Y in patients with angina pectoris.

Authors:  J G Clarke; G J Davies; R Kerwin; D Hackett; S Larkin; D Dawbarn; Y Lee; S R Bloom; M Yacoub; A Maseri
Journal:  Lancet       Date:  1987-05-09       Impact factor: 79.321

9.  Potency and receptors involved in coronary vasoconstriction caused by neuropeptide Y(NPY).

Authors:  Y Aizawa; M Satoh; M Aizawa; T Funazaki; S Niwano; S Miyajima; A Shibata
Journal:  Jpn Heart J       Date:  1987-11

10.  Neuropeptide Y is a vasoconstrictor of human coronary arteries.

Authors:  C J Tseng; D Robertson; R T Light; J R Atkinson; R M Robertson
Journal:  Am J Med Sci       Date:  1988-07       Impact factor: 2.378

View more
  2 in total

1.  Cardiac sympathetic activation circumvents high-dose beta blocker therapy in part through release of neuropeptide Y.

Authors:  Jonathan D Hoang; Siamak Salavatian; Naoko Yamaguchi; Mohammed Amer Swid; Hamon David; Marmar Vaseghi
Journal:  JCI Insight       Date:  2020-06-04

2.  Neuropeptide Y is a prejunctional inhibitor of vagal but not sympathetic inotropic responses in guinea-pig isolated left atria.

Authors:  A P Serone; J A Angus
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.